Following closely on the heels of the news that its deal to merge Pfizer’s consumer health business with its own, GSK has announced that Nucala (mepolizumab) had secured approval from the European Commission for two new delivery methods for patients with severe eosinophilic asthma to self-administer.
The drug, which is the only monthly anti-IL5 biologic approved in Europe, was authorised in a pre-filled pen and a pre-filled safety syringe form, based on Phase 3a data from two real-world studies which indicated that 98% of patients and 100% of caregivers were able to successfully ad
![Het beste uit je content halen met een kloppend verhaal [10 stappen]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/businesswoman-working-at-creative-office-2023-11-27-05-24-05-utc-1-80x60.jpg)
